Skip to content

The effect of sugammadex on muscle relaxation recovery and pulmonary complications in elderly patients with sarcopenia after hip surgery

The effect of sugammadex on muscle relaxation recovery and pulmonary complications in elderly patients with sarcopenia after hip surgery

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115353
Enrollment
Unknown
Registered
2025-12-25
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Sugammadex Sodium Group (Group S):After the operation, patients in Group S were transferred to the post-anesthesia care unit (PACU) and received an intravenous injection of sugammadex sodium at a dose
Neostigmine Group (Group N):After the operation, patients in Group N were transferred to the post-anesthesia care unit (PACU) and received an intravenous injection of neostigmine (0.04 mg/kg) combined

Sponsors

Anhui NO.2 Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Patients with unilateral hip fracture caused by falling injury, who underwent artificial femoral head replacement (AFHR) or proximal femoral nail antirotation (PFNA) surgery 2.Preoperative chest CT examination was performed to measure the skeletal muscle mass index (SMI) at the level of the 12th thoracic vertebra. For males: SMI < 42.6cm^2/m^2; For females: SMI < 30.6cm^2/m^2 3.Rocuronium or vecuronium was used as muscle relaxants during anesthesia induction and maintenance

Exclusion criteria

Exclusion criteria: 1. Pre-existing lower limb motor dysfunction, with a history of underlying diseases such as coronary heartdisease, cerebral infarction and stroke 2. Non-first-time hip fracture, traffic accident, multiple fractures, congenital or acquired hip dysplasia,pathological fracture 3.Non-AFHR Or PFNA surgical procedure 4. Conservative treatment 5.Cisatracurium besilate was selected for induction 6. Severe hepatic and renal insufficiency 7. Allergic to related drugs, etc.

Design outcomes

Primary

MeasureTime frame
The time for the train-of-four ratio (TOFr) to recover to 0.9 after drug administration and the time from the end of surgery to extubation;TOFr at the time of extubation;Duration of PACU Stay;Record the occurrence of post-extubation hypoxemia (SpO? < 90%) and calculate the incidence of residual neuromuscular block (RNMB: TOFr < 0.9 at extubation);Evaluate and record the maximum grip strength before the usual surgery, 5 minutes after extubation, and upon discharge from the PACU, then calculate the differences.;The occurrence of postoperative pulmonary complications (PPCs) from the end of surgery to prior to hospital discharge;

Secondary

MeasureTime frame
Total number of presses, number of effective presses, and number of rescue analgesia administrations of the patient-controlled analgesia (PCA) pump within 48 hours after surgery;Number of cases of postoperative nausea and vomiting (PONV);Incidence of other adverse reactions (such as arrhythmia, dizziness, fever, etc.);The condition of the first postoperative ambulation and the duration of postoperative hospital stay;

Countries

China

Contacts

Public ContactLi Tao

Anhui NO.2 Provincial People's Hospital

18656634576@163.com+86 551 6427 2148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026